Form 4: Schrodinger CSO Sells Shares for Tax Obligations

Schrodinger's EVP and Chief Scientific Officer, Robert Lorne Abel, sold 1,230 shares of common stock to cover tax liabilities from RSU vesting.

Summary

• Robert Lorne Abel, EVP, Chief Scientific Officer, Platform at Schrodinger, Inc. (SDGR), reported a sale of common stock.
• The transaction involved 1,230 shares of common stock sold at a price of $13.51 per share.
• The sale occurred on February 9, 2026.
• This sale was executed under a Rule 10b5-1 trading plan adopted on June 13, 2023.
• The purpose of the sale was to satisfy withholding tax liability incurred upon the vesting of restricted stock units (RSUs).
• Following this transaction, Robert Lorne Abel beneficially owns 19,385 shares, which includes 15,137 unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a routine, non-discretionary sale by an executive to cover tax obligations related to RSU vesting, executed under a pre-arranged trading plan.

Positives

• The sale was non-discretionary, executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned event rather than a reaction to new information.

Negatives

• No specific negatives identified as the sale was for tax purposes and not a discretionary divestment.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategy.

Management Comments

• "This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2023."
• "The sale represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ('RSUs')."
• "The sale does not represent a discretionary trade by the reporting person."

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax liabilities upon RSU vesting are a common and routine occurrence in the technology and biotechnology sectors. These transactions are typically pre-scheduled under Rule 10b5-1 plans to avoid accusations of insider trading and do not usually signal a change in management's outlook on the company.

Comparison to Industry Standards

• This transaction is a standard practice for executive compensation and tax management, aligning with common industry practices for publicly traded companies where executives receive equity compensation. For example, similar tax-related sales are frequently observed at companies like Pfizer (PFE) or Moderna (MRNA) when their executives' stock options or RSUs vest.

Stakeholder Impact

• Minimal impact on shareholders, as this is a routine, non-discretionary sale for tax purposes and does not reflect a change in the executive's confidence or the company's fundamentals.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by an executive to cover tax liabilities associated with RSU vesting, executed under a pre-arranged Rule 10b5-1 plan. Such transactions are common and do not typically indicate a change in the company's fundamental outlook or the executive's confidence. Therefore, the filing itself does not provide new information that would warrant a change in investment thesis, leading to a "hold" recommendation.

Keywords

Schrodinger, SDGR, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Liability, Rule 10b5-1, Executive Compensation, Beneficial Ownership